Nat. Rev. Neurol. doi: /nrneurol

Slides:

Advertisements

Similar presentations

Nat. Rev. Neurol. doi: /nrneurol

Advertisements

Chronic acquired demyelinating polyneuropathies

Hereditary sensory and autonomic neuropathy type 1

Figure 3 Life expectancy at birth in all countries included

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Histopathology of low-grade glioma

Figure 1. Absence of anti–neurofascin-155 (NF155) antibodies in combined central and peripheral demyelination (CCPD)‏ Absence of anti–neurofascin-155 (NF155)

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Systemic immune responses to cryptococcal antigen

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 3D magnetic resonance neurography

Nat. Rev. Neurol. doi: /nrneurol

RED BLOOD CELLS.

Figure 4 Neuromyelitis optica spectrum disorder brain lesions

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Co-stimulatory receptors as immunomodulatory targets

P. James B. Dyck, MD, Jennifer A. Tracy, MD Mayo Clinic Proceedings

Figure 2 Proposed model of therapeutic mechanisms of AHSCT

Figure 1 Percent positivity by clinical feature Overall, 6

Nat. Rev. Endocrinol. doi: /nrendo

Figure 3 LGI1 and Caspr2 immunohistochemistry on rat brain

Figure 1 Pathogenesis of diabetic neuropathy

Nat. Rev. Urol. doi: /nrurol

Figure Clinical course of acute neuritis and NMDA receptor (NMDAR) encephalitis, sural nerve biopsy, and detection of NMDAR antibodies(A) Approximately.

Figure 2 Algorithm for immunosuppressive treatment

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Principles of therapeutic ultrasound

Figure 1 Clinical correlates of neurodegeneration in MS

Volume 30, Issue 2, Pages (May 2001)

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Lifestyle and environmental factors affect

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Anatomical patterns of neuropathy

Figure 1 Neuromuscular junction in myasthenia gravis (MG)

Nat. Rev. Neurol. doi: /nrneurol

Volume 69, Issue 2, Pages (January 2011)

Figure 1 The node of Ranvier

Figure 3 Current model of immunopathogenesis in CIDP

Figure 2 Brain biopsy Brain biopsy (A) Double staining with anti-aquaporin-4 (AQP4) antibody (dark green) and Luxol fast blue (blue) is shown. Loss of.

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Frequency of vertigo and dizziness syndromes

Figure 2 Logistical requirements for autologous

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Comparison of 7.0T and 3.0T MRI (patients 5 and 6)‏

Elizabeth A. Normand, Matthew N. Rasband Developmental Cell

Figure 2 Cellular pathways implicated in CIPN

(A) Confocal image of a skin biopsy taken from the finger of a healthy subject illustrating different subtypes of sensory fibre: PGP 9.5 is used as an.

Diseases Involving Myelin

(A) Confocal image of a skin biopsy taken from the finger of a healthy subject illustrating different subtypes of sensory fibre: PGP 9.5 is used as an.

Figure 4 Representative images of skin biopsy sample

Figure 1 Timing of the effects of deep brain stimulation

Figure 5 Interaction between infarction and amyloid deposition

Figure 1 A large number of genes are potentially associated with CIPN

Nat. Rev. Neurol. doi: /nrneurol

Fishing for Biomarkers with Antigen Mimics

Figure 1 Chronic inflammation and DNA damage in people with SLE

Nat. Rev. Neurol. doi: /nrneurol

Figure 1. Antibodies to MOG in a proportion of adult patients with MS

Figure 3 Blood–brain barrier breakdown promotes neurodegeneration

Figure 1 Examples illustrating gating strategy for fluorescence-activated cell sorting (FACS)‏ Examples illustrating gating strategy for fluorescence-activated.

Figure 2 Clinical and autoantibody status of 2 CNTN1 or NF155+ patients not receiving rituximab Despite corticosteroids and methotrexate treatment, patient.

Figure 1 Clinical status and autoantibody titers in rituximab-treated patients with anti-CNTN1/NF155 chronic inflammatory demyelinating polyneuropathy.

Figure 2 Histopathological features in CIDP

Figure ND5 and MCARNE phenotype

Figure 6 Multiple target epitopes exist in the N-terminal domains of Caspr2 (A) Multidomain deletion constructs of Caspr2 were generated to determine which.

Figure 2 Cell-based assay demonstrating differential binding of AChR antibodies to the adult and fetal receptorsThe fetal (gamma subunit specific) and.

Figure 3 Bilateral optic atrophy and sural nerve biopsy of patient AII-2 Bilateral optic atrophy and sural nerve biopsy of patient AII-2 (A) Red-free photographs.

Histograms showing periods until an improvement of one Hughes grade from onset. Histograms showing periods until an improvement of one Hughes grade from.

Figure 3. Verification of GluRd2 as the target antigen of the patient's antineural autoantibodies Verification of GluRd2 as the target antigen of the patient's.

Presentation transcript:

Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.84 Figure 4 Features of CIDP associated with autoantibodies that target NF155 Figure 4 | Features of CIDP associated with autoantibodies that target NF155. a,b | The reactivity to paranodal antigens (seen here as a yellow signal resulting from the merger of red and green fluoresence) of serum from patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and anti-NF155 antibodies (red fluorescence) is lost in nerve preparations from neurofascin-null mice (part b) compared with those from wild-type mice (part a). Green fluorescence, CASPR1; blue fluorescence, P0 (myelin protein zero). c,d | Septate-like junctions, which link the Schwann cell paranodal loops to the axon, can be seen on sural nerve biopsy samples from seronegative patients with CIDP (part c) but are lost in patients with anti-NF155 antibodies (part d). ml, myelin loop; Nfasc, neurofascin. Reproduced with permission from Elsevier © Vallat, J.-M. et al. Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-neurofascin 155 antibodies. Neuromuscul. Disord. 27, 290–293 (2016). Reproduced with permission from Elsevier © Vallat, J.-M. et al. Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-neurofascin 155 antibodies. Neuromuscul. Disord. 27, 290–293 (2016). Querol, L. et al. (2017) Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.84